Clinical Trials · NCT03434119
Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
- Phase
- Phase 3
- Recruitment status
- Terminated
- Sponsor
- Sanofi
- Enrollment
- 241
- Start date
- Feb 2018
- Locations
- 85 sites, United States
- Primary endpoint
- Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26